Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14337907 | 0.80 | TRPA1 (0.44) | USP2TSHRSLC6A3SLC6A4HSD11B1 | |
| SCHEMBL26081074 | 0.78 | SLC6A3 (0.38) | SLC6A3SLC6A4METAP2IDO1 | |
| SCHEMBL23365166 | 0.74 | CYP46A1 (0.45) | METAP2 | |
| SCHEMBL15188013 | 0.73 | KMT2A (0.39) | USP2TSHR | |
| SCHEMBL15168718 | 0.73 | TACR1 (0.41) | USP2TSHRSLC6A4IDO1 | |
| SCHEMBL2192517 | 0.71 | OPRL1 (0.54) | USP2TSHR | |
| SCHEMBL2346342 | 0.71 | OPRL1 (0.54) | USP2TSHR | |
| SCHEMBL2192474 | 0.71 | OPRL1 (0.54) | USP2TSHR | |
| SCHEMBL26081071 | 0.71 | KDM4E (0.47) | USP2TSHRSLC6A3SLC6A4IDO1 | |
| SCHEMBL12345530 | 0.69 | ESR1 (0.47) | USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | USP2 1918/4885TSHR 4693/4885SLC6A3 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.